Heuschen G, Heuschen U A, Herfarth C
Chirurgische Klinik und Poliklinik, Universität Heidelberg.
Chirurg. 1998 Oct;69(10):1028-34.
Primary sclerosing cholangitis (PSC) is generally associated with ulcerative colitis (UC). The disease typically progresses slowly, but ultimately, and leads to cirrhosis, liver failure or bile duct cancer. PSC patients with simultaneous ulcerative colitis are also at higher risk for colorectal cancer. At the present time, there is no effective treatment for PSC, although preliminary data show encouraging results after treatment with ursodeoxycholic acid. However, there are no data concerning the delay or prevention of progress of the disease with this drug, because follow-up time is not yet long enough. Isolated bile duct strictures should be treated endoscopically. The possible effect of proctocolectomy on the course of PSC is controversial. Liver transplantation is the therapy of choice for PSC in its final stage. The 5-year survival rate (89%) is significantly better than after transplantation for other indications. Patients with ulcerative colitis have to be followed up by lifelong colonoscopy. Although the course of UC after transplantation is mostly asymptomatic, these patients are at higher risk for colorectal cancer.
原发性硬化性胆管炎(PSC)通常与溃疡性结肠炎(UC)相关。该疾病通常进展缓慢,但最终会导致肝硬化、肝衰竭或胆管癌。同时患有溃疡性结肠炎的PSC患者患结直肠癌的风险也更高。目前,尚无针对PSC的有效治疗方法,尽管初步数据显示熊去氧胆酸治疗后有令人鼓舞的结果。然而,尚无关于该药物延缓或预防疾病进展的数据,因为随访时间还不够长。孤立性胆管狭窄应通过内镜治疗。全直肠结肠切除术对PSC病程的可能影响存在争议。肝移植是PSC终末期的首选治疗方法。其5年生存率(89%)明显优于其他适应症的移植后生存率。患有溃疡性结肠炎的患者必须终身接受结肠镜随访。尽管移植后UC的病程大多无症状,但这些患者患结直肠癌的风险更高。